vs
Side-by-side financial comparison of Apollo Commercial Real Estate Finance, Inc. (ARI) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.
VERACYTE, INC. is the larger business by last-quarter revenue ($139.1M vs $73.3M, roughly 1.9× Apollo Commercial Real Estate Finance, Inc.). Apollo Commercial Real Estate Finance, Inc. runs the higher net margin — 39.9% vs 20.6%, a 19.2% gap on every dollar of revenue. On growth, VERACYTE, INC. posted the faster year-over-year revenue change (21.5% vs 4.0%). Over the past eight quarters, VERACYTE, INC.'s revenue compounded faster (10.2% CAGR vs -4.6%).
Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.
Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.
ARI vs VCYT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $73.3M | $139.1M |
| Net Profit | $29.2M | $28.7M |
| Gross Margin | — | 72.7% |
| Operating Margin | 39.7% | 16.3% |
| Net Margin | 39.9% | 20.6% |
| Revenue YoY | 4.0% | 21.5% |
| Net Profit YoY | -28.2% | — |
| EPS (diluted) | $0.19 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $139.1M | ||
| Q4 25 | $73.3M | $140.6M | ||
| Q3 25 | $61.6M | $131.9M | ||
| Q2 25 | $70.9M | $130.2M | ||
| Q1 25 | $65.8M | $114.5M | ||
| Q4 24 | $70.5M | $118.6M | ||
| Q3 24 | $71.6M | $115.9M | ||
| Q2 24 | $81.1M | $114.4M |
| Q1 26 | — | $28.7M | ||
| Q4 25 | $29.2M | $41.1M | ||
| Q3 25 | $50.8M | $19.1M | ||
| Q2 25 | $20.7M | $-980.0K | ||
| Q1 25 | $26.0M | $7.0M | ||
| Q4 24 | $40.7M | $5.1M | ||
| Q3 24 | $-91.5M | $15.2M | ||
| Q2 24 | $35.8M | $5.7M |
| Q1 26 | — | 72.7% | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% |
| Q1 26 | — | 16.3% | ||
| Q4 25 | 39.7% | 26.4% | ||
| Q3 25 | 82.8% | 17.4% | ||
| Q2 25 | 29.4% | -4.0% | ||
| Q1 25 | 39.7% | 2.5% | ||
| Q4 24 | 57.9% | 3.5% | ||
| Q3 24 | -127.8% | 10.4% | ||
| Q2 24 | 44.2% | 4.0% |
| Q1 26 | — | 20.6% | ||
| Q4 25 | 39.9% | 29.3% | ||
| Q3 25 | 82.4% | 14.5% | ||
| Q2 25 | 29.3% | -0.8% | ||
| Q1 25 | 39.5% | 6.2% | ||
| Q4 24 | 57.7% | 4.3% | ||
| Q3 24 | -127.9% | 13.1% | ||
| Q2 24 | 44.1% | 5.0% |
| Q1 26 | — | $0.35 | ||
| Q4 25 | $0.19 | $0.50 | ||
| Q3 25 | $0.34 | $0.24 | ||
| Q2 25 | $0.12 | $-0.01 | ||
| Q1 25 | $0.16 | $0.09 | ||
| Q4 24 | $0.25 | $0.07 | ||
| Q3 24 | $-0.69 | $0.19 | ||
| Q2 24 | $0.23 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $139.8M | $439.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $1.3B |
| Total Assets | $9.9B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $439.1M | ||
| Q4 25 | $139.8M | $362.6M | ||
| Q3 25 | $245.9M | $315.6M | ||
| Q2 25 | $177.6M | $219.5M | ||
| Q1 25 | $166.4M | $186.1M | ||
| Q4 24 | $317.4M | $239.1M | ||
| Q3 24 | $194.3M | $274.1M | ||
| Q2 24 | $174.7M | $235.9M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.9B | $1.3B | ||
| Q3 25 | $1.9B | $1.3B | ||
| Q2 25 | $1.8B | $1.2B | ||
| Q1 25 | $1.9B | $1.2B | ||
| Q4 24 | $1.9B | $1.2B | ||
| Q3 24 | $1.9B | $1.2B | ||
| Q2 24 | $2.0B | $1.1B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $9.9B | $1.4B | ||
| Q3 25 | $9.5B | $1.4B | ||
| Q2 25 | $9.8B | $1.3B | ||
| Q1 25 | $8.8B | $1.3B | ||
| Q4 24 | $8.4B | $1.3B | ||
| Q3 24 | $9.1B | $1.3B | ||
| Q2 24 | $9.3B | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.5M | $35.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 4.88× | 1.23× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $35.2M | ||
| Q4 25 | $142.5M | $52.6M | ||
| Q3 25 | $31.7M | $44.8M | ||
| Q2 25 | $63.2M | $33.6M | ||
| Q1 25 | $39.3M | $5.4M | ||
| Q4 24 | $200.3M | $24.5M | ||
| Q3 24 | $47.2M | $30.0M | ||
| Q2 24 | $50.2M | $29.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $48.8M | ||
| Q3 25 | — | $42.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $26.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 34.7% | ||
| Q3 25 | — | 31.8% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 23.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 2.4% |
| Q1 26 | — | 1.23× | ||
| Q4 25 | 4.88× | 1.28× | ||
| Q3 25 | 0.62× | 2.34× | ||
| Q2 25 | 3.05× | — | ||
| Q1 25 | 1.51× | 0.76× | ||
| Q4 24 | 4.93× | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | 1.40× | 5.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARI
Segment breakdown not available.
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
